Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/16786

Title: Strategies to manage hepatitis C virus (HCV) disease burden
Authors: Wedemeyer, H.
Duberg, A. S.
Buti, M.
Rosenberg, W. M.
Frankova, S.
Esmat, G.
Ormeci, N.
Van Vlierberghe, H.
Gschwantler, M.
Akarca, U.
Aleman, S.
Balik, I.
Berg, T.
Bihl, F.
Bilodeau, M.
Blasco, A. J.
Brandao Mello, C. E.
Bruggmann, P.
Calinas, F.
Calleja, J. L.
Cheinquer, H.
Christensen, P. B.
Clausen, M.
Coelho, H. S. M.
Cornberg, M.
Cramp, M. E.
Dore, G. J.
Doss, W.
El-Sayed, M. H.
Ergor, G.
Estes, C.
Falconer, K.
Felix, J.
Ferraz, M. L. G.
Ferreira, P. R.
Garcia-Samaniego, J.
Gerstoft, J.
Giria, J. A.
Goncales, F. L., Jr.
Guimaraes Pessoa, M.
Hezode, C.
Hindman, S. J.
Hofer, H.
Husa, P.
Idilman, R.
Kaberg, M.
Kaita, K. D. E.
Kautz, A.
Kaymakoglu, S.
Krajden, M.
Krarup, H.
Laleman, W.
Lavanchy, D.
Lazaro, P.
Marinho, R. T.
Marotta, P.
Mauss, Stefan
Mendes Correa, M. C.
Moreno, C.
Muellhaupt, B.
Myers, R. P.
Nemecek, V.
Ovrehus, A. L. H.
Parkes, J.
Peltekian, K. M.
Ramji, A.
Razavi, H.
Reis, N.
Roberts, S. K.
Roudot-Thoraval, F.
Ryder, S. D.
Sarmento-Castro, R.
Sarrazin, C.
Semela, D.
Sherman, M.
Shiha, G. E.
Sperl, J.
Starkel, P.
Stauber, R. E.
Thompson, A. J.
Urbanek, P.
Van Damme, P.
van Thiel, I.
VANDIJCK, Dominique
Vogel, W.
Waked, I.
Weis, N.
Wiegand, J.
Yosry, A.
Zekry, A.
Negro, F.
Sievert, W.
Gower, E.
Issue Date: 2014
Citation: JOURNAL OF VIRAL HEPATITIS, 21 (S1), p. 60-89
Abstract: The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCVrelated morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3–5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
Notes: Wedemeyer, H (reprint author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str, D-30625 Hannover, Germany. wedemeyer.heiner@mh-hannover.de
URI: http://hdl.handle.net/1942/16786
DOI: 10.1111/jvh.12249
ISI #: 000333893200004
ISSN: 1352-0504
Category: A1
Type: Journal Contribution
Validation: ecoom, 2015
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
published version3.06 MBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.